{"id":44796,"date":"2025-10-28T13:29:31","date_gmt":"2025-10-28T05:29:31","guid":{"rendered":"https:\/\/flcube.com\/?p=44796"},"modified":"2025-10-28T13:29:32","modified_gmt":"2025-10-28T05:29:32","slug":"novartis-asciminib-enters-chinas-spark-program-for-pediatric-chronic-myeloid-leukemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44796","title":{"rendered":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia"},"content":{"rendered":"\n<p>The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) Asciminib (ABL001) hydrochloride tablets\/microcapsules have been proposed for inclusion in the <strong>\u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d<\/strong>. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Program Inclusion<\/strong> \u2013 Asciminib will be the first targeted therapy in the SPARK program to address a rare pediatric leukemia indication.<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong> \u2013 The drug was approved for marketing by the NMPA in May\u202f2025 and is now positioned for accelerated pediatric development.<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong> \u2013 The SPARK program provides streamlined review, financial incentives, and expanded market access for innovative anti\u2011tumor agents in children.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action\"><strong>Mechanism of Action<\/strong><\/h2>\n\n\n\n<p>Asciminib is a <strong>novel allosteric inhibitor<\/strong> targeting the BCR\u2011ABL1 kinase:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Binding Site<\/strong> \u2013 Binds to the <strong>myristoyl pocket (STAMP)<\/strong>\u2014an allosteric site distinct from conventional tyrosine\u2011kinase inhibitors (TKIs).<\/li>\n\n\n\n<li><strong>Conformational Change<\/strong> \u2013 Induces a structural shift that blocks kinase activity without competing with ATP.<\/li>\n\n\n\n<li><strong>Clinical Advantage<\/strong> \u2013 Offers an alternative to standard TKIs, potentially reducing resistance and toxicity in pediatric patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-impact-on-pediatric-oncology\"><strong>Impact on Pediatric Oncology<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First of Its Kind<\/strong> \u2013 Provides a precision\u2011medicine option specifically engineered for children with Ph\u207a\u202fCML\u2011CP.<\/li>\n\n\n\n<li><strong>Accelerated Development<\/strong> \u2013 Leveraging SPARK\u2019s incentives may shorten the time to market and enhance clinical trial recruitment.<\/li>\n\n\n\n<li><strong>Broader Reach<\/strong> \u2013 Aligns with China\u2019s national priority to expand access to life\u2011saving treatments for children.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44797,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[16,865,68],"class_list":["post-44796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-cancer","tag-nyse-nvs","tag-pediatric-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44796\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44796\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T05:29:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-28T05:29:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia\",\"datePublished\":\"2025-10-28T05:29:31+00:00\",\"dateModified\":\"2025-10-28T05:29:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796\"},\"wordCount\":287,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2803.webp\",\"keywords\":[\"Cancer\",\"NYSE: NVS\",\"Pediatric drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44796#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44796\",\"name\":\"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2803.webp\",\"datePublished\":\"2025-10-28T05:29:31+00:00\",\"dateModified\":\"2025-10-28T05:29:32+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\\\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44796\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44796#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44796","og_locale":"en_US","og_type":"article","og_title":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia","og_description":"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.","og_url":"https:\/\/flcube.com\/?p=44796","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-28T05:29:31+00:00","article_modified_time":"2025-10-28T05:29:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44796#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44796"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia","datePublished":"2025-10-28T05:29:31+00:00","dateModified":"2025-10-28T05:29:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44796"},"wordCount":287,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","keywords":["Cancer","NYSE: NVS","Pediatric drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44796#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44796","url":"https:\/\/flcube.com\/?p=44796","name":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44796#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","datePublished":"2025-10-28T05:29:31+00:00","dateModified":"2025-10-28T05:29:32+00:00","description":"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today that Novartis\u2019 (NYSE: NVS) asciminib hydrochloride tablets\/microcapsules (brand\u2011name ABL001) have been proposed for inclusion in the \u201cPilot Program to Encourage the Research and Development of Anti\u2011tumor Drugs for Children (SPARK Program)\u201d. The drug is intended for the treatment of Philadelphia chromosome\u2011positive chronic myeloid leukemia in the chronic phase (Ph\u207a\u202fCML\u2011CP) in pediatric patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44796#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44796"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44796#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","width":1080,"height":608,"caption":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44796#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Asciminib Enters China\u2019s SPARK Program for Pediatric Chronic Myeloid Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44796"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44796\/revisions"}],"predecessor-version":[{"id":44798,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44796\/revisions\/44798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44797"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}